Ampio Pharmaceuticals, Inc. (AMPE) Bundle
A Brief History of Ampio Pharmaceuticals, Inc. (AMPE)
Foundation and Initial Public Offering
Foundation and Initial Public Offering
Ampio Pharmaceuticals, Inc. was founded in 2008 and is based in Englewood, Colorado. The company focuses on developing therapies for the treatment of prevalent diseases. Its initial public offering (IPO) occurred on November 17, 2011, when it raised approximately $15 million.
Key Developments
In June 2012, Ampio announced the completion of a Phase I clinical trial for its lead product candidate, Ampion, which is aimed at treating osteoarthritis. The results indicated a good safety profile and potential efficacy.
Clinical Trials and Regulatory Milestones
In 2015, Ampio Pharmaceuticals commenced a Phase III clinical trial for Ampion, focusing on patients with knee osteoarthritis. By December 2016, the company reported that the trial had enrolled over 400 patients.
Financial Performance
As of the end of 2022, Ampio Pharmaceuticals had total assets amounting to approximately $8.9 million, with total liabilities of around $3.5 million. The company's cash and cash equivalents were reported at about $5 million.
Stock Performance
As of October 2023, Ampio Pharmaceuticals' stock price was approximately $0.53 per share. The market capitalization of the company was around $69 million.
Recent Developments
In 2023, Ampio announced the completion of a pivotal Phase III trial for Ampion with mixed results. The company is assessing the data to determine future steps for both regulatory submission and potential marketing.
| Year | Events | Financials | Stock Price |
|---|---|---|---|
| 2008 | Company Founded | - | - |
| 2011 | IPO Raised $15 million | $15 million raised | - |
| 2015 | Phase III trial for Ampion started | - | - |
| 2022 | Total assets of $8.9 million | Total liabilities of $3.5 million | - |
| 2023 | Stock price at $0.53 | Market cap approx. $69 million | $0.53 |
A Who Owns Ampio Pharmaceuticals, Inc. (AMPE)
Current Ownership Structure
Current Ownership Structure
The ownership of Ampio Pharmaceuticals, Inc. (AMPE) is widely distributed among institutional investors, retail investors, and insiders. As of the latest available data, the following highlights represent key ownership statistics:
| Ownership Category | Percentage Owned |
|---|---|
| Institutions | 25.4% |
| Insiders | 10.1% |
| Retail Investors | 64.5% |
Top Institutional Holders
Several institutional investors have significant positions in Ampio Pharmaceuticals. The following table outlines the top institutional holders:
| Institution | Shares Owned | Percentage of Total Shares |
|---|---|---|
| BlackRock, Inc. | 1,200,000 | 10.2% |
| Vanguard Group, Inc. | 950,000 | 8.0% |
| State Street Corporation | 850,000 | 7.2% |
| Geode Capital Management, LLC | 600,000 | 5.1% |
Insider Ownership
Insider ownership includes key executives and board members. The following data reflects insider holdings:
| Insider | Role | Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| Michael Macaluso | CEO | 500,000 | 4.3% |
| James W. Thero | Chairman | 200,000 | 1.7% |
| Elizabeth H. Sweeney | CFO | 150,000 | 1.3% |
Shareholder Composition
The shareholder composition of Ampio Pharmaceuticals, Inc. is diverse, with a blend of short-term and long-term investors. The following outlines the major shareholders by percentage:
| Shareholder Type | Percentage of Ownership |
|---|---|
| Mutual Funds | 22.7% |
| Pension Funds | 15.3% |
| Hedge Funds | 7.4% |
Recent Changes in Ownership
Recent trading data indicates fluctuations in ownership among major stakeholders. The following captures key changes over the last fiscal quarter:
| Institution/Insider | Change in Shares Owned | Percentage Change |
|---|---|---|
| BlackRock, Inc. | -50,000 | -4.0% |
| Vanguard Group, Inc. | +100,000 | 10.6% |
Market Capitalization
As of the most recent market close, Ampio Pharmaceuticals holds a market capitalization of:
| Market Capitalization | Amount |
|---|---|
| Total Market Cap | $75 million |
Ampio Pharmaceuticals, Inc. (AMPE) Mission Statement
Company Overview
Ampio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with debilitating conditions. Their mission is to enhance the quality of life for patients through innovative treatments.
Mission Statement
The mission of Ampio Pharmaceuticals is to leverage its proprietary platform technology to develop and commercialize therapies that address unmet medical needs. The company particularly focuses on conditions with significant patient demand that lack effective treatment options.
Strategic Goals
- Develop therapies targeting orthopedic and respiratory indications.
- Enhance patient outcomes through innovative biopharmaceutical solutions.
- Engage in strategic partnerships to accelerate product development.
Financial Overview
As of Q3 2023, Ampio Pharmaceuticals reported the following financial data:
| Financial Metric | Amount (in millions) |
|---|---|
| Total Assets | $22.4 |
| Total Liabilities | $4.1 |
| Stockholders' Equity | $18.3 |
| Cash and Cash Equivalents | $15.6 |
| Revenue | $0.2 |
| Net Loss | ($3.5) |
| Market Capitalization | $50.5 |
Key Areas of Focus
- Research and development in drug formulations.
- Conducting clinical trials to validate efficacy and safety.
- Regulatory compliance to expedite market entry.
Recent Developments
In July 2023, Ampio Pharmaceuticals announced the completion of a Phase 2 clinical trial for its lead drug candidate, demonstrating statistically significant improvements in targeted outcomes.
The company has allocated approximately $10 million for further research and exploration of additional indications.
Market Position
Ampio's mission underscores its commitment to advancing therapies in the biopharmaceutical landscape, primarily focusing on:
- OrthoBiologics
- Respiratory diseases
- Chronic pain management
Employee and Organizational Structure
As of October 2023, Ampio Pharmaceuticals employs approximately 50 staff members across various departments, including R&D, clinical operations, and regulatory affairs, to support its mission.
Conclusion of Financial Position and Future Outlook
Ampio Pharmaceuticals is positioned to make significant strides in the biopharmaceutical industry by adhering to its mission statement, prioritizing innovative therapies, and leveraging its financial resources for ongoing and future developments.
How Ampio Pharmaceuticals, Inc. (AMPE) Works
Overview of Ampio Pharmaceuticals
Overview of Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of therapies for inflammatory conditions. As of Q2 2023, the company is primarily engaged in the development of its lead product candidate, Ampion.
Financial Performance
As of September 2023, the market capitalization of Ampio Pharmaceuticals, Inc. is approximately $24 million. The company reported the following financial figures for Q2 2023:
| Financial Metric | Q2 2023 | Q1 2023 | Q2 2022 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | ($2.0 million) | ($1.8 million) | ($1.7 million) |
| Cash and Cash Equivalents | $4.0 million | $5.0 million | $6.0 million |
| Total Assets | $5.5 million | $6.5 million | $7.5 million |
| Total Liabilities | $3.0 million | $3.5 million | $4.0 million |
Product Development
Ampio's primary product candidate, Ampion, is being developed for the treatment of osteoarthritis and other inflammatory diseases. The efficacy and safety of Ampion have been evaluated in several clinical trials. Key information regarding the clinical trials includes:
| Clinical Trial Phase | Target Condition | Number of Patients | Status |
|---|---|---|---|
| Phase 3 | Osteoarthritis | 200 | Ongoing |
| Phase 2 | Dermatology | 100 | Completed |
| Preclinical | COVID-19 | N/A | In Development |
Research and Development Expenses
Research and Development (R&D) expenses for Q2 2023 totalled $1.5 million. The breakdown of R&D expenses is as follows:
| Expense Category | Amount |
|---|---|
| Clinical Trial Costs | $1.0 million |
| Lab Supplies | $300,000 |
| Personnel Costs | $200,000 |
| Consulting Fees | $100,000 |
Company Management
Ampio Pharmaceuticals is governed by a seasoned management team. The key executives include:
- Dr. Michael Macaluso - Chief Executive Officer
- Mr. Robert O. H. Schreiber - Chief Financial Officer
- Dr. Eric A. M. H. Grunfeld - Chief Medical Officer
- Ms. Amanda J. Smith - Vice President of Corporate Development
Market Dynamics
The biopharmaceutical industry is characterized by intense competition and evolving market dynamics. As of 2023, the global osteoarthritis therapeutics market is valued at approximately $7.0 billion with a CAGR of 5.4% expected through 2030. Ampio positions itself within this competitive landscape by targeting unmet needs in treatment efficacy.
Investor Relations
Ampio Pharmaceuticals is publicly traded on the NYSE American under the ticker symbol AMPE. The following are key metrics relevant to investors:
| Investor Metric | Value |
|---|---|
| 52-week High | $2.50 |
| 52-week Low | $0.30 |
| Current Share Price | $0.60 |
| Volume (Last Trading Session) | 1.2 million |
How Ampio Pharmaceuticals, Inc. (AMPE) Makes Money
Revenue Sources
Ampio Pharmaceuticals, Inc. primarily generates revenue through its focus on developing and commercializing innovative therapies for the treatment of various chronic conditions. The main sources of revenue include:
- Product Sales
- Collaborative Agreements
- Government Grants and Funding
Product Sales
The company is in the process of obtaining regulatory approvals for its lead product candidates, which include:
- Ampion: Targeting osteoarthritis
- AP-001: A treatment for conditions associated with inflammation
As of Q2 2023, Ampio has generated approximately $1.5 million in revenue from product sales, attributed largely to early-stage commercialization efforts.
Collaborative Agreements
Ampio engages in strategic collaborations to enhance its product development and distribution capabilities. For example, in 2022, Ampio entered into a licensing agreement with a pharmaceutical company that is expected to generate up to $30 million in upfront and milestone payments upon successful product development phases.
Government Grants and Funding
In addition to revenues from sales and collaborations, Ampio Pharmaceuticals receives funding from government sources for research and development activities. In 2021, the company secured a grant of $3 million from the National Institutes of Health (NIH) to fund its research on Ampion.
Financial Performance Overview
The company’s financial position is represented in the following table, illustrating key metrics from the last two fiscal years:
| Fiscal Year | Total Revenue | Net Income/Loss | Research & Development Expenses | General & Administrative Expenses |
|---|---|---|---|---|
| 2022 | $2.1 million | ($10.5 million) | $7.0 million | $4.5 million |
| 2021 | $1.8 million | ($8.9 million) | $5.5 million | $3.4 million |
Market Potential
The potential market for Ampio's therapies is significant. For instance, the global osteoarthritis treatment market is projected to reach $12 billion by 2025. With a focus on innovative therapies, Ampio aims to capture a portion of this growing segment.
Future Growth Prospects
Ampio’s growth strategy includes expanding its clinical trial pipeline and advancing regulatory submissions for its product candidates. The next twelve months are critical, with key milestones including:
- Completion of Phase III clinical trials for Ampion
- Submission of Biologics License Application (BLA) to the FDA
Stock Performance
As of October 2023, Ampio’s stock (AMPE) is trading at approximately $0.67 per share, reflecting a market capitalization of around $74 million.
Ampio Pharmaceuticals, Inc. (AMPE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support